News

Current News from ECCO 2023: Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice

20. 9. 2023 Source: Intestinal Inflammations

At the 18th ECCO Congress, held in March 2023 in Copenhagen, results from a Spanish real-world study were presented. This study evaluated the efficacy and safety of tofacitinib in the treatment of ulcerative colitis (UC), including the impact of this drug on extraintestinal manifestations of the disease and immune-mediated diseases.

Proton radiotherapy in patients with nasopharyngeal carcinoma increases chances of successful treatment

Nasopharyngeal carcinoma mainly affects younger people. It tends to be aggressive but responds very well to treatment –⁠ up to 85% of patients with this diagnosis can achieve long-term tumor…

20. 9. 2023 Source: Proton Radiotherapy

Early Implementation of Highly Effective Therapy for Multiple Sclerosis

The ongoing debate about changing the approach to treating relapsing-remitting multiple sclerosis (RRMS) from an escalation strategy to the early implementation of highly effective therapy (HET) is…

20. 9. 2023 Source: Neurology - Multiple Sclerosis

Sequential Treatment of Schizophrenia –⁠ Interactive Case Study

Sequential treatment of schizophrenia helps psychiatrists clarify the stage of the patient's treatment and how to further guide pharmacotherapy. The following case study illustrates the possibilities...

14. 9. 2023 Source: Modern Treatment of Schizophrenia

Treatment Options for Advanced Parkinson's Disease Using Medical Devices (DAT)

A new treatment option for advanced Parkinson's disease (PD) using medical devices (DAT −⁠ device-aided therapy) is the intestinal infusion gel containing levodopa, entacapone, and carbidopa (LECIG).…

14. 9. 2023 Source: Parkinson's Disease

Identification of patients with advanced Parkinson's disease suitable for device-aided therapy (DAT)

To properly implement device-aided therapy in Parkinson's disease (PD) management, it is essential to timely identify patients in advanced stages of the disease who might benefit from this…

14. 9. 2023 Source: Parkinson's Disease

Do real-world clinical practice data confirm the results of cenobamate treatment in the clinical program?

A recent study by Spanish authors presents the largest dataset of patients with published cenobamate treatment results under prolonged observation in real-world clinical practice at the time of…

13. 9. 2023 Source: Epilepsy

Cenobamate in the Therapy of Pharmacoresistant Epilepsy in a Warfarinized Patient –⁠ A Case Study

A case study from Czech practice presents a patient with pharmacoresistant epilepsy and concurrent warfarin medication for heart valve replacement, where the INR value remained within the…

13. 9. 2023 Source: Epilepsy

Meta-analysis of Efficacy and Safety of Antidiabetics in Treating Gestational DM

What efficacy and safety do insulin, metformin, or the sulfonylurea derivative glibenclamide (glyburide) offer in lowering glucose levels in women with gestational diabetes? The authors of a…

13. 9. 2023 Source: Modern Treatment of Diabetes

Revolutionary Change in the Paradigm of Multiple Sclerosis (MS) Treatment in the Czech Republic

At the beginning of last year, there was a revolutionary change in the paradigm of multiple sclerosis (MS) treatment in the Czech Republic. Patients with MS and an unfavorable prognosis no longer have...

11. 9. 2023 Source: Neurology - Multiple Sclerosis

How to Determine the Optimal Target Value of Intraocular Pressure in Glaucoma Treatment?

Glaucoma remains the second most common cause of blindness in Europe. Therapy needs to be individualized with regard to the severity of the condition, expected lifespan, and the rate of disease…

8. 9. 2023 Source: Treatment of Glaucoma

Hypertrophic Cardiomyopathy: When Bigger Does Not Mean Better

Hypertrophic cardiomyopathy (HCM) is a hereditary disease that, in some patients, proceeds asymptomatically, while others struggle with arrhythmias or heart failure, and in some individuals, the…

7. 9. 2023 Source: Hypertrophic Cardiomyopathy (HCM)

Why does the heart enlarge? Myosin mutation and hypertrophic cardiomyopathy may be the culprits

The genetic basis of hypertrophic cardiomyopathy was discovered only about a quarter-century ago. Since then, researchers have gathered a wealth of knowledge about the effects of causal mutations.…

7. 9. 2023 Source: Hypertrophic Cardiomyopathy (HCM)

Current View on Gestational Diabetes Mellitus in Theory and Practice

We dedicated one of the episodes of our podcast meditalks+ to the issue of gestational diabetes mellitus (GDM), focusing on aspects of care related to general practitioners. In a conversation with …

7. 9. 2023 Source: Modern Treatment of Diabetes

ESMO Recommendations for the Treatment of Low-Risk Myelodysplastic Syndrome

The priority in the treatment of low-risk myelodysplastic syndrome (MDS) is managing cytopenia, primarily anemia, as well as neutropenia and thrombocytopenia. The following summary of recommendations…

6. 9. 2023 Source: proLékaře.cz

1 … 23 24 25 26 27 … 115

Back Filter by speciality

Remove filters

Popular this week